PHARMARON(03759.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 750.19 million, YoY increase of 6.96%

NewTimeSpace News: August 20, 2026, PHARMARON(03759.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 7.6 billion, increased by 17.92% YoY; Net Profit stood at CNY 711.7 million, YoY increase of 9.05%; Profit Attributable to Shareholders stood at CNY 750.19 million, YoY increase of 6.96%; Basic Earnings Per Share (EPS) stood at CNY 0.41.

In terms of profitability, PHARMARON Gross Profit changed from CNY 2.17 billion in the same period last year to CNY 2.47 billion in the current period, increased by CNY 302.67 million; gross profit margin changed from 33.72% in the same period last year to 32.58% in the current period, decreased by 1.14 percentage points; net profit changed from CNY 652.63 million in the same period last year to CNY 711.7 million in the current period, increased by CNY 59.07 million; net profit margin changed from 10.13% in the same period last year to 9.37% in the current period, decreased by 0.76 percentage points. 

In terms of earnings quality, PHARMARON Operating Profit changed from CNY 939.58 million in the same period last year to CNY 1.01 billion in the current period, increased by CNY 66.24 million; Operating Profit Margin changed from 14.59% in the same period last year to 13.24% in the current period, decreased by 1.35 percentage points. 

In terms of financial soundness, PHARMARON Debt-to-Asset Ratio changed from 40.99% in the same period last year to 41.1% in the current period, increased by 0.11 percentage points; Total Equity changed from CNY 14.869 billion in the same period last year to CNY 17.051 billion in the current period, increased by CNY 2.18 billion; Current Liabilities changed from CNY 4.98 billion in the same period last year to CNY 8.72 billion in the current period, increased by CNY 3.74 billion; Quick Ratio changed from 1.42 in the same period last year to 0.92 in the current period, decreased by 0.5 percentage points. 

In terms of R&D investment focus, PHARMARON R&D Expenses changed from CNY 250.46 million in the same period last year to CNY 295.83 million in the current period, increased by CNY 45.37 million; R&D to Total Revenue Ratio stayed unchanged from 3.89% in the same period last year to 3.89% in the current period, remained flat. 

By the close of trading on August 20, 2026, PHARMARON(03759) saw a gain of 7.7% in its share price, closing at HKD 33.86. The full-day turnover stood at HKD 611.06 million, showing significant volume increase, with the latest market capitalization at HKD 12.13 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.